Time Limited Therapies for the Management of Chronic Lymphocytic Leukemia (CLL): American Journal of Hematology: Vol 97, No S2

I consent to Wiley Online Library’s Terms of Use and processing of my personal data as disclosed in Wiley’s Privacy Policy.I consent to my personal information being transferred outside of the People’s Republic of China as laid out in Wiley’s Privacy Policy.*(Optional) I consent to special offers, newsletter & promotions from Wiley. See Privacy Policy for more details.

Tools

Submit an article

Journal Metrics

Subscribe to this journal

Related Title

LATEST ISSUE
Volume 6, Issue 4
August 2025

Posts by AjHematology

American Journal of Hematology

Journal list menu

Tools

Follow journal

American Journal of Hematology: Volume 97, Issue S2

Time Limited Therapies for the Management of Chronic Lymphocytic Leukemia (CLL)

Publication of this Supplement is made possible by funding from BeiGene and an educational grant from Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Funding from both supporters was not conditioned upon the specific selection of the articles, authors, or topics contained herein. The supporters have not reviewed nor commented on the content.

TABLE OF CONTENTS

Table of Contents

CRITICAL REVIEWS

Management of front line chronic lymphocytic leukemia

Management of relapsed/refractory Chronic Lymphocytic Leukemia

Approach to a patient with “double refractory” chronic lymphocytic leukemia: “Double, double toil and trouble” (Shakespeare)

Unusual complications in the management of chronic lymphocytic leukemia

Tools

More from this journal

Related Title

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

American Journal of Hematology

Journal list menu

Tools

Follow journal

American Journal of Hematology: Volume 97, Issue S2

Time Limited Therapies for the Management of Chronic Lymphocytic Leukemia (CLL)

Download PDFs

Publication of this Supplement is made possible by funding from BeiGene and an educational grant from Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Funding from both supporters was not conditioned upon the specific selection of the articles, authors, or topics contained herein. The supporters have not reviewed nor commented on the content.

TABLE OF CONTENTS

Table of Contents

CRITICAL REVIEWS

Management of front line chronic lymphocytic leukemia

Management of relapsed/refractory Chronic Lymphocytic Leukemia

Approach to a patient with “double refractory” chronic lymphocytic leukemia: “Double, double toil and trouble” (Shakespeare)

Unusual complications in the management of chronic lymphocytic leukemia

Sign up for email alerts

Tools

More from this journal

Related Title